PL3053578T3 - Skojarzona terapia przeciwnowotworowa z zastosowaniem związku azabicyklicznego - Google Patents

Skojarzona terapia przeciwnowotworowa z zastosowaniem związku azabicyklicznego

Info

Publication number
PL3053578T3
PL3053578T3 PL14849447T PL14849447T PL3053578T3 PL 3053578 T3 PL3053578 T3 PL 3053578T3 PL 14849447 T PL14849447 T PL 14849447T PL 14849447 T PL14849447 T PL 14849447T PL 3053578 T3 PL3053578 T3 PL 3053578T3
Authority
PL
Poland
Prior art keywords
cancer therapy
combination cancer
azabicyclo compound
azabicyclo
compound
Prior art date
Application number
PL14849447T
Other languages
English (en)
Inventor
Hiromi MURAOKA
Akira KANOH
Original Assignee
Taiho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co., Ltd. filed Critical Taiho Pharmaceutical Co., Ltd.
Publication of PL3053578T3 publication Critical patent/PL3053578T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL14849447T 2013-09-30 2014-09-29 Skojarzona terapia przeciwnowotworowa z zastosowaniem związku azabicyklicznego PL3053578T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013205500 2013-09-30
EP14849447.9A EP3053578B1 (en) 2013-09-30 2014-09-29 Combination cancer therapy using azabicyclo compound
PCT/JP2014/075846 WO2015046498A1 (ja) 2013-09-30 2014-09-29 アザ二環式化合物を用いたがん併用療法

Publications (1)

Publication Number Publication Date
PL3053578T3 true PL3053578T3 (pl) 2021-06-14

Family

ID=52743621

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14849447T PL3053578T3 (pl) 2013-09-30 2014-09-29 Skojarzona terapia przeciwnowotworowa z zastosowaniem związku azabicyklicznego

Country Status (13)

Country Link
US (6) US9694001B2 (pl)
EP (1) EP3053578B1 (pl)
JP (1) JP6197041B2 (pl)
KR (1) KR101767859B1 (pl)
AU (1) AU2014325016C1 (pl)
DK (1) DK3053578T3 (pl)
ES (1) ES2848706T3 (pl)
HU (1) HUE053617T2 (pl)
PL (1) PL3053578T3 (pl)
PT (1) PT3053578T (pl)
RU (1) RU2657783C2 (pl)
TW (1) TWI667237B (pl)
WO (1) WO2015046498A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3053578T3 (da) * 2013-09-30 2021-02-01 Taiho Pharmaceutical Co Ltd Kombinationscancerterapi ved hjælp af azabicycloforbindelse
CA2985033C (en) * 2015-05-12 2020-02-25 Taiho Pharmaceutical Co., Ltd. Crystalline form ii of 3-ethyl-4-{3-isopropyl-4-(4-(1-methyl-1h-pyrazol-4-yl)-1h-imidazol-1-yl)-1h­pyrazol0[3,4-b]pyridin-1-yl}benzamide
US20200129487A1 (en) * 2017-06-30 2020-04-30 Taiho Pharmaceutical Co., Ltd. Chemotherapy for cancer using azabicyclo compound
RU2020113456A (ru) * 2017-09-15 2021-10-15 Тайхо Фармасьютикал Ко., Лтд. Профилактическое и/или терапевтическое средство против заболеваний, связанных с экспрессией ido
JP7518080B2 (ja) * 2019-08-06 2024-07-17 大鵬薬品工業株式会社 アザ二環式化合物とポリアデノシン5’二リン酸リボースポリメラーゼ阻害剤を用いたがん併用療法
RU2748135C2 (ru) * 2020-09-07 2021-05-19 Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр радиологии» Министерства здравоохранения Российской Федерации (ФГБУ «НМИЦ радиологии» Минздрава России) СПОСОБ КОМБИНИРОВАННОГО ЛЕЧЕНИЯ МЕСТНО-РАСПРОСТРАНЕННЫХ ФОРМ РАКА ШЕЙКИ МАТКИ IIB-IIIB(T2b-T3bN0(1)M0) СТАДИЙ
AU2023282693A1 (en) 2022-06-10 2025-01-02 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition containing pimitespib
JPWO2023238930A1 (pl) 2022-06-10 2023-12-14
KR20260049608A (ko) 2023-08-24 2026-04-14 다이호야쿠힌고교 가부시키가이샤 아자 2 고리형 화합물과 항안드로겐제를 사용한 암 병용 요법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1337275A4 (en) 2000-11-02 2007-05-09 Sloan Kettering Inst Cancer METHOD FOR ENHANCING THE EFFICACY OF CYTOTOXIC AGENTS USING HSP 90 INHIBITORS
CN101357134A (zh) * 2003-03-14 2009-02-04 大鹏药品工业株式会社 抗肿瘤效果增强剂和抗肿瘤剂
EP1746099A1 (en) * 2004-12-23 2007-01-24 DeveloGen Aktiengesellschaft Mnk1 or Mnk2 inhibitors
WO2007014362A1 (en) 2005-07-27 2007-02-01 A.S. Incorporated Corrosion inhibition method for use in boiler water systems
JP5305909B2 (ja) * 2005-09-21 2013-10-02 フォーエスシー アクチエンゲゼルシャフト ヒストンデアセチラーゼインヒビターとしてのスルホニルピロール塩酸塩
JO2783B1 (en) 2005-09-30 2014-03-15 نوفارتيس ايه جي Compounds 2-Amino-7, 8-dihydro-6H-Bayredo (3,4-D) Pyrimidine-5-Ones
AR061185A1 (es) * 2006-05-26 2008-08-13 Chugai Pharmaceutical Co Ltd Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas.
CL2008000629A1 (es) 2007-03-01 2008-08-29 Chugai Pharmaceutical Co Ltd Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer.
AU2010269674B2 (en) 2009-07-10 2014-01-16 Taiho Pharmaceutical Co., Ltd. Azabicyclo compound and salt thereof
DK3053578T3 (da) * 2013-09-30 2021-02-01 Taiho Pharmaceutical Co Ltd Kombinationscancerterapi ved hjælp af azabicycloforbindelse

Also Published As

Publication number Publication date
US20200276171A1 (en) 2020-09-03
EP3053578A1 (en) 2016-08-10
RU2657783C2 (ru) 2018-06-15
KR20160045900A (ko) 2016-04-27
RU2016116777A (ru) 2017-11-09
AU2014325016A1 (en) 2016-04-21
WO2015046498A1 (ja) 2015-04-02
AU2014325016B2 (en) 2017-10-26
US11918562B2 (en) 2024-03-05
EP3053578B1 (en) 2020-12-23
US10849886B2 (en) 2020-12-01
TWI667237B (zh) 2019-08-01
US20160228417A1 (en) 2016-08-11
PT3053578T (pt) 2021-02-09
KR101767859B1 (ko) 2017-08-11
US20220016090A1 (en) 2022-01-20
US20250161280A1 (en) 2025-05-22
US20170216261A1 (en) 2017-08-03
HUE053617T2 (hu) 2021-07-28
US20240156792A1 (en) 2024-05-16
US9694001B2 (en) 2017-07-04
JPWO2015046498A1 (ja) 2017-03-09
TW201522336A (zh) 2015-06-16
US11166943B2 (en) 2021-11-09
JP6197041B2 (ja) 2017-09-13
ES2848706T3 (es) 2021-08-11
EP3053578A4 (en) 2017-03-01
DK3053578T3 (da) 2021-02-01
AU2014325016C1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
IL245731A0 (en) Combined treatment for cancer
GB201322725D0 (en) Cancer therapy
PL3033086T3 (pl) Terapia skojarzona do leczenia nowotworów złośliwych
GB2513596B (en) Image-guided radiotherapy
SG10201913730RA (en) Cancer therapy
PT3053578T (pt) Terapêutica de combinação de cancro usando composto de azabiciclo
SG11201507847UA (en) Cancer therapy
ZA201508212B (en) Bacteriophage therapy
EP3007756A4 (en) Catheter-assisted tumor treatment
ZA201507755B (en) Tumor-selective combination therapy
EP3044593A4 (en) Cancer therapy
EP2961412A4 (en) CANCER THERAPY
GB201310755D0 (en) Therapy
EP3007704A4 (en) Combination therapy
EP2934500A4 (en) COMBINATION THERAPY AGAINST CANCER
PT2948129T (pt) Compostos terapêuticos
GB201308039D0 (en) Photodynamic therapy
GB201307269D0 (en) Combination Therapy
GB201314286D0 (en) Therapeutic Compounds
GB201312499D0 (en) Therapeutic compounds
GB201518731D0 (en) Tumour Therapy
PL3016948T3 (pl) 2-acyloaminotiazole do leczenia nowotworów
GB201320905D0 (en) Therapeutic compounds
EP3013332A4 (en) Cancer treatment
GB201317213D0 (en) Cancer Therapy